Jasper and its stem cell con­di­tion­ing an­ti­body earn a tick­et to Nas­daq in lat­est SPAC re­verse merg­er

Ed­i­tor’s note: In­ter­est­ed in fol­low­ing bio­phar­ma’s fast-paced IPO mar­ket? You can book­mark our IPO Track­er here.

An­oth­er biotech SPAC deal has land­ed as the glut of blank-check com­pa­nies con­tin­ues to make waves in the in­dus­try.

Thurs­day’s win­ner is Jasper Ther­a­peu­tics, join­ing forces with Am­pli­tude Health­care Ac­qui­si­tion Corp. in a $100 mil­lion re­verse-merg­er, Jasper an­nounced. The deal al­so comes with a PIPE fi­nanc­ing of an ad­di­tion­al $100 mil­lion, set­ting Jasper up with a $490 mil­lion mar­ket cap once the merg­er clos­es in the third quar­ter.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER